CD4+ T cell kinetics and activation in human immunodeficiency virus-infected patients who remain viremic despite long-term treatment with protease inhibitor-based therapy

Journal of Infectious Diseases

Volumn 185, Issue 3, 2002, Pages 315-323

  Deeks, Steven G ^a   Hoh, Rebecca ^a   Grant, Robert M ^b,c   Barbour, Jason D ^b   Narvaez, Amy ^a   Cesar, Denise ^d   Abe, Ken ^d   Hanley, Mary Beth ^b   Hellmann, Nicholas S ^c   Petropoulos, Christos J ^c   McCune, Joseph M ^a,b   Hellerstein, Marc K ^a,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b GLADSTONE INSTITUTE OF VIROLOGY AND IMMUNOLOGY   (United States)

^c Viro Logic   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEINASE INHIBITOR;

ADULT; ARTICLE; CELL COUNT; CELL CYCLE; CELL FRACTIONATION; CELL KINETICS; CONTROLLED STUDY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERM CARE; MAJOR CLINICAL STUDY; PHENOTYPE; PRIORITY JOURNAL; STEADY STATE; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME; TURNOVER TIME; VIREMIA; VIRUS LOAD; VIRUS VIRULENCE;

ADULT; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL CYCLE; CROSS-SECTIONAL STUDIES; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; IMMUNOPHENOTYPING; LYMPHOCYTE ACTIVATION; RNA, VIRAL; VIREMIA;

EID: 0036468120     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/338467     Document Type: Article

References (32)

1. + cell counts of 200 per cubic millimeter or less
2. Long lasting recovery of CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease
3. Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: Results of AIDS Clinical Trials Group Protocol 315
4. Sustained CD4 T cell response after virologic failure of protease inhibitor based regimens in HIV infected patients
5. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study
6. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy
7. Virologic and immunologic consequences of discontinuing combination antiretroviral drug therapy in HIV-infected patients with detectable viremia
8. Directly measured kinetics of circulating T lymphocytes in normal and HIV-infected humans
9. Factors influencing T cell turnover in HIV-1-seropositive patients
10. + T cell depletion in HIV disease
11. Serum levels of tumor necrosis factor (TNF)-alpha and soluble TNF receptors in human immunodeficiency virus type 1 infection - Correlations to clinical immunologic and virologic parameters
12. T-cell division in human immunodeficiency virus (HIV-1) infection is mainly due to immune activation: A longitudinal analysis in patients before and during highly active antiretroviral therapy (HAART)
13. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage
14. Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: Results of AIDS Clinical Trials Group Protocol 315
15. Normalization of immune activation in lymphoid tissue following highly active antiretroviral therapy
16. Measurement of cell proliferation by labeling of DNA with stable isotope-labeled glucose; studies in vitro, in animals and in humans
17. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1
18. + T cell renewal in early HIV infection: Effect of highly active antiretroviral therapy
19. Influence of glucose loading and of injected insulin on hepatic glucose output
20. + T cell turnover in HIV-infected patients
21. + T cells go out of stock
22. T-cell homeostasis in HIV infection is neither failing nor blind: Modified cell counts reflect an adaptive response of the host
23. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: A composite of redistribution and proliferation
24. T cell turnoverin SIV infection
25. Impaired replication of protease inhibitor-resistant HIV-1 in human thymus
26. Altered viral fitness of HIV-1 following failure of protease inhibitor-based therapy
27. + T cells in human immunodeficiency virus-infected patients experiencing virologic treatment failure: Role of changes in thymic output and T cell death
28. Immunologic profile of human immunodeficiency virus-infected patients during viral remission and relapse on antiretroviral therapy
29. Determinants of sustainable CD4 lymphocyte count increases in response to antiretroviral therapy
30. The use of and response to second-line protease inhibitor regimens: Results from the EuroSIDA study
31. Immunologic memory and protective immunity: Understanding their relation
32. The impact of HIV on naive T-cell homeostasis